Redefining Criteria to Ensure Adequate Sentinel Lymph Node Biopsy With Dual Tracer for Breast Cancer
BackgroundFor sentinel lymph node biopsy (SLNB) in patients with breast cancer, the dual tracer of blue dye and radioisotope with the 10% rule that all nodes with radioactive count of 10% or more of the hottest node ex vivo should be removed is widely accepted. However, the cut-off point of radioact...
Main Authors: | Li Xu, Jiqiao Yang, Zhenggui Du, Faqing Liang, Yanyan Xie, Quanyi Long, Jie Chen, Helin Zeng, Qing Lv |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.588067/full |
Similar Items
-
Accuracy of Sentinel Lymph Node Biopsy in Breast Cancer: Pitfalls in the Application of Single Tracers
by: Yang J, et al.
Published: (2020-05-01) -
Sentinel Lymph Node Biopsy Results in Early-Stage Breast Cancer
by: Ahmet Kocakuflak, et al.
Published: (2011-06-01) -
Sentinel lymph node biopsy for breast cancer using methylene blue: a new anatomical landmark involving intercostobrachial and medial pectoral nodes
by: I Gusti Ngurah Gunawan Wibisana, et al.
Published: (2020-10-01) -
Sentinel lymph node biopsy in breast neoplasms
by: Višnjić Milan, et al.
Published: (2009-01-01) -
Sentinel lymph node mapping using methylene blue and Technetium-99 in early endometrial cancer
by: Fariba Behnamfar, et al.
Published: (2017-11-01)